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Abstract: For patients with complex or other severe forms of PTSD, particularly in cases with dis-
sociative symptoms, different treatment approaches have been suggested. However, the influence
of somatoform dissociation on the effectiveness of trauma-focused treatment has hardly ever been
studied. This study aims to test the hypotheses that (1) PTSD patients reporting a low level and
those reporting a high level of somatoform dissociative symptoms would both benefit from an
intensive trauma-focused treatment, and that (2) somatoform dissociative symptoms would allevi-
ate. Participants were 220 patients with severe PTSD, enrolled in an intensive treatment program
combining EMDR therapy and prolonged exposure therapy, without a preceding stabilization phase.
Trauma history was diversified, and comorbidity was high. PTSD symptoms (CAPS-5 and PCL-5)
and somatoform dissociative symptoms (SDQ-5 and SDQ-20) were assessed at pre-treatment, post-
treatment and at six months after completion of treatment. The course of both PTSD and somatoform
dissociative symptoms was compared for individuals reporting low and for those reporting high
levels of somatoform dissociative symptoms. Large effect sizes were observed regarding PTSD symp-
toms reduction for patients with both low and high levels of somatoform dissociation. Somatoform
dissociation did not impact improvement in terms of PTSD symptom reduction. The severity of
somatoform dissociative symptoms decreased significantly in both groups. This decrease was greater
for those with a positive screen for a dissociative disorder. These results add further support to the
notion that the presence of strong somatoform dissociative symptoms in patients with PTSD does
not necessarily call for a different treatment approach. Clinical implications are discussed.
Keywords: posttraumatic stress disorder; somatoform dissociative symptoms; dissociation; intensive
trauma-focused treatment; EMDR; prolonged exposure; compartmentalization
1. Introduction
For patients with severe or complex forms of PTSD, such as those with dissociative
symptoms, it has been suggested that a modified treatment approach, i.e., a phase-based
approach, might be more appropriate than regular trauma-focused treatment [1,2]. Treat-
ment would then, for example, start with a stabilization phase focused on skill training in
emotion regulation, working on competences in social interactions, and grounding skills in
order to decrease dissociative symptoms, before commencing the trauma-focused part of
the treatment (see, e.g., [3]). In this view, dissociative symptoms are considered a distinct
form of PTSD. Indeed, in some studies it was found that PTSD patients with additional
dissociative symptoms benefit less from a trauma-focused treatment than those without dis-
sociative symptoms [4]. On the other hand, other studies found that dissociative symptoms
did not predict trauma-focused treatment efficacy [5,6]. A recent meta-analysis showed
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that dissociation had no significant effect on treatment outcome, and that the impact of dis-
sociation was about zero [7]. Additionally, some studies found that direct trauma-focused
therapy actually led to a decrease in dissociative symptoms, e.g., [8,9]. Another view is,
therefore, that dissociative symptoms are associated with PTSD, rather than being a distinct
form of PTSD. Consecutively, it has been asserted that trauma-focused therapy should
be considered as the first-choice treatment for PTSD patients with additional dissociative
symptoms [5,10].
However, dissociation is a broad concept, referring to a variety of phenomena. In most
studies hitherto, mainly psychological dissociation has been studied. Van der Hart, Ni-
jenhuis, Steele, and Brown [11] pointed out that besides disruptions to mental functions
and a subjective experience of an altered state of consciousness (psychological dissociation,
e.g., derealization and depersonalization), disruptions in bodily functions and sensations,
such as loss of motor control, analgesia, seizures, and pain, could also be considered
forms of dissociation, referred to as somatoform dissociation. To clarify the use of the
term dissociation, Holmes et al. [12] classified dissociative phenomena into two different
qualitative categories: detachment and compartmentalization. The first category refers
to an altered state of consciousness, i.e., psychological dissociative phenomena, whereas
the latter refers to a separation of normally integrated mental processes, leading to a
sudden inability to control certain actions or cognitive processes, i.e., somatoform dis-
sociation [12,13]. Neurologically, detachment seems to be characterized by a top-down
inhibition of limbic emotional systems and an increased activation of right prefrontal cortex
regions, illustrative of a decrease in feelings of anxiety [12,14,15]. Compartmentalization,
on the other hand, has been found to be related to reduced thickness of the left caudal
anterior cingulate cortex [16], allegedly related to emotion regulation problems and fear
extinction deficits [17,18], both important underlying processes for trauma-related treat-
ment [19,20]. Compartmentalization might, therefore, reduce the likelihood of benefiting
from trauma-focused treatment.
As with psychological dissociation, a phase-based treatment approach has been rec-
ommended for those with somatoform dissociative symptoms [21]. Thus far, however,
the influence of somatoform dissociation on trauma-focused treatment outcomes in PTSD
patients has hardly ever been studied. A study by Myers et al. [22] showed that prolonged
exposure therapy for patients with PTSD and psychogenic non-epileptic seizures (PNES), a
specific form of somatoform dissociation, was effective for both PTSD and PNES symptoms.
Thus, although it is largely unknown how somatoform dissociation affects trauma-focused
treatment outcomes in PTSD patients, some preliminary evidence suggests that somatoform
dissociation, like psychological dissociation, is responsive to trauma-focused treatments.
The purpose of the present study was to determine the extent to which PTSD patients
with somatoform dissociative symptoms would respond to trauma-focused treatment in
comparison to patients without somatoform dissociative symptoms. Based on the above
mentioned findings regarding conversion disorder and our previous studies with patients
with psychological dissociation [9,23], we hypothesized that both patients reporting a low
level and those reporting a high level of somatoform dissociative symptoms (i.e., fulfilling
the criteria of a positive screen for a dissociative disorder) would benefit from an intensive
trauma-focused treatment, and that the severity of somatoform dissociative symptoms
would decrease significantly during treatment.
2. Materials and Methods
2.1. Participants
Participants were patients who were referred to an intensive treatment program at the
Psychotrauma Expertise Centrum (PSYTREC) in the Netherlands. A total of 284 patients
enrolled for treatment, of whom 244 gave informed consent for participation in our clinical
research. Pre-treatment scores on the main measurements were missing for 25 patients,
who were therefore excluded from the analyses. This resulted in a final intention-to-treat
(ITT) sample of 219 patients (see also Figure 1).
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Figure 1. Flowchart for the intention-to-treat sample used for main analysis.
2.2. Procedure
Pre-treatment assessment took place during intake using the Clinician-Administered
PTSD Scale (CAPS), the Mini-International Neuropsychiatric Interview (MINI), and the
Somatoform Dissociation Questionnaire-20 (SDQ-20). Additionally, the inclusion crite-
ria were checked and when met, patients were asked to sign a treatment contract and
informed consent form for research purposes. Inclusion criteria were being at least 18 years
old, and having a PTSD diagnosis according to the 5th edition of the Diagnostic and
Statistical Manual of Mental Disorders (DSM-5) [24]. Exclusion criteria were not having
sufficient knowledge of the Dutch language to be able to complete the assessments, and a
suicide attempt in the three months prior to intake. After the intake sessions, the intensive
eight-day treatment program started. Daily assessment with the Somatoform Dissociation
Questionnaire-5 (SDQ-5) and the Dutch version of the 20-item PTSD Checklist for DSM-5
(PCL-5) took place during the therapy session in the morning. Nine days after treatment,
post-treatment assessments were carried out using both the CAPS and the SDQ-20. As-
sessors of all measures were blind to the study hypotheses. The study was performed in
accordance with the principles of the Declaration of Helsinki. The Medical Ethics Review
Committee of VU University Medical Centre (registered with the US Office for Human
Research Protections (OHRP) as IRB00002991, FWA number FWA00017598) has confirmed
that the Medical Research Involving Human Subjects Act (WMO) does not apply to this
study. For this reason, an official approval of this study by the committee was not required.
2.3. Treatment
Treatment consisted of eight days and was provided over two weeks, with four
treatment days per week. Patients received one Prolonged Exposure (PE) session of 90 min
in the morning and one Eye Movement Desensitization and Reprocessing (EMDR) therapy
session of 90 min in the afternoon. Therapy sessions were provided by psychologists who
were trained in both forms of psychotherapy. EMDR therapy was provided according to
the Dutch version of the EMDR standard protocol [25]. PE therapy was provided largely
according to the protocol by Foa, Hembree, and Rothbaum [26], albeit the recording of
the sessions and homework assignments were omitted due to the intensive treatment
format. Importantly, no interventions were specifically aimed at reducing or coping with
dissociative symptoms. Every patient was treated by multiple therapists, adhering to the
principle of therapist rotation [27]. Additionally, patients participated during the day in
physical activities in a group, and attended daily psychoeducation meetings in a group
format. See Woudenberg et al. [28] for a detailed description of the treatment program.
2.4. Measurements
PTSD symptom severity was measured using the Dutch version of the Clinician-
Administered PTSD Scale for DSM-5 (CAPS-5), a well-validated semi-structured diagnostic
interview [29,30]. This consists of 30 items, corresponding to the DSM-5 PTSD symp-
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toms, measured over the past month. The Somatoform Dissociation Questionnaire-20
(SDQ-20) [31] was used to measure the severity of somatoform dissociative symptoms.
This 20-item questionnaire has been well-validated, and scoring has been proven robust to
suggestion [32]. To operationalize high levels of somatoform dissociation, we used a cut-off
score of 35, which was used in earlier studies as an indication of the possible presence of a
dissociative disorder (positive screen group) [21,32]. Additionally, the SDQ-5 was admin-
istered on a daily basis during treatment. This 5-item questionnaire is derived from the
SDQ-20 and has high sensitivity and specificity in the screening of somatoform dissociative
symptoms [32]. The course of PTSD symptoms during treatment was measured using the
Dutch version of the 20-item PTSD Checklist for DSM-5 over the past 24 h (PCL-5) [33,34],
which has excellent reliability and validity [35]. Comorbidity was assessed using the Dutch
version of the Mini-International Neuropsychiatric Interview (MINI) [36,37]. The MINI is a
validated structured interview to classify DSM-IV disorders and assess suicidal risk [37,38].
2.5. Data Analyses
Analyses were performed using IBM SPSS Statistics for Windows (version 24). All
analyses were carried out on the basis of intention-to-treat. To test the main hypotheses,
we conducted a simple linear regression analysis with SDQ-20 scores at intake as the
independent variable, and the difference between pre-treatment and post-treatment CAPS
scores as the dependent variable. Additionally, a factorial mixed ANOVA was conducted,
with the CAPS-5 and SDQ-20 scores, respectively, over time (pre-treatment, post-treatment)
as the within-subjects factor, and a positive screen for a dissociative disorder according to
the SDQ-20 (≥35 vs. <35) as the between-subjects factor. To analyze the course of symptoms
during treatment, a mixed ANOVA was conducted with the daily PCL-5 scores and SDQ-5
scores, respectively, as the within-subjects factor, and the possible presence of a dissociative
disorder, as suggested by the SDQ-20 scores, as the between-subjects factor. Because the
assumption of sphericity was violated for the total PCL-5 scores (χ2 = 315.05, p < 0.001)
and the total SDQ-5 scores (χ2 = 710.00, p < 0.001), Greenhouse–Geisser corrections were
applied. Cohen’s [39] rule of thumb was used to interpret Cohen’s d effect sizes. Because
only limited follow-up data were available at 6 months follow-up (n = 119), we explored
the influence of somatoform dissociative symptoms on treatment outcome at 6 months
follow-up in a separate analysis.
3. Results
3.1. Patient Characteristics
At pre-treatment, 13.2% of the patients scored ≥ 35 on the SDQ-20, indicative of a
dissociative disorder. Patients scoring above and below this cut-off score on the SDQ-20
at intake did not differ in age, t(217) = 1.60, p = 0.11, or gender, χ2(1) = 0.93, p = 0.33, nor
was there a difference in the proportion that experienced physical abuse, χ2 (1) = 1.47,
p = 0.23, or armed violence, χ2(1) = 0.58, p = 0.45. Patients in the positive screen group
had experienced sexual abuse more often, χ2 (1) = 7.06, p = 0.01, and 75.9% also met the
criteria for the dissociative subtype of PTSD, which was significantly more than those in
the negative screen group (41.4%), χ2 (1) = 11.90, p = 0.001. A total of 14 patients (6.4%)
dropped out of treatment; this proportion was not different between the two subgroups,
χ2(1) = 0.48, p = 0.49. Sample characteristics can be found in Table 1.
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SDQ-20 (n = 29)
Negative Screen on
SDQ-20 (n = 190)
Gender Women (%) 174 (79.5%) 25 (86.2%) 149 (78.4%)
Mean age (SD) 39.73 (12.27) 36.34 (11.51) 40.25 (12.32)
Three most frequent types of
trauma (%)
Physical abuse 90% 96.6% 88.9%
Sexual abuse 82.2% 100% 79.5%
Armed violence 55.3% 62.1% 54.2%
Comorbidity
Depression 53.0% 62.1% 51.6%
Anxiety disorder 48.4% 31.0% 51.1%
Suicidality 74.4% 89.7% 72.1%
Dissociative subtype (%) 101 (46.1%) 22 (75.9%) 79 (41.6%)
Note. ITT = intention-to-treat. Types of trauma were measured using the Life Events Checklist for DSM-5 (LEC).
Comorbidity was measured using the Mini-International Neuropsychiatric Interview (MINI). The dissociative
subtype was assessed using the Clinician-Administered PTSD Scale (CAPS). For the Somatoform Dissociation
Questionnaire-20 (SDQ-20), a cut-off score of 35 was applied.
3.2. Influence of Somatoform Dissociation on Treatment Outcome
A simple linear regression, using pre-treatment SDQ-20 scores as the independent
variable, and the difference between pre-treatment and post-treatment CAPS scores as the
dependent variable, showed that the severity of somatoform dissociative symptoms was
not associated with treatment outcome, F(1, 211) = 0.15, p = 0.67, R2 = 0.001. A significant
main effect of time on decreases in PTSD symptom severity (i.e., CAPS-5 scores) was found,
F(1, 217) = 323.03, p < 0.001, Cohen’s d = 2.34. No significant main effect of group was
found, F(1, 217) = 1.72, p = 0.19, which indicates that there was no significant difference
between both groups in terms of PTSD symptom decrease. Additionally, no significant
interaction effect was found between the groups and total CAPS-5 scores, F(1, 217) = 0.09,
p = 0.93, suggesting that a pre-treatment positive screen for a dissociative disorder did not
affect treatment outcomes in terms of a decrease in PTSD symptoms (see Figure 2). Means
and SDs on both points of measurement can be found in Table 2.




M (SD) Cohen’s d
CAPS (SD)
Positive screen 45.10 (7.16) 18.07 (13.30) 2.53
Negative screen 42.94 (7.49) 15.62 (14.88) 2.32
Total 43.22 (7.47) 15.94 (14.68) 2.34
SDQ-20 (SD)
Positive screen 40.93 (6.50) 27.38 (6.82) 2.03
Negative screen 25.39 (4.13) 22.59 (3.56) 0.79
Total 27.45 (6.93) 23.22 (4.43) 0.73
Regarding PCL-5 scores during treatment, a significant main effect of time was found,
i.e., total PCL-5 scores decreased significantly during treatment, F(4.42, 879.44) = 160.78,
p < 0.001, partial η2 = 0.45. No significant main effect of group was found, suggesting no
significant differences in PTSD symptom reduction between those in the positive screen
group and those in the negative screen group, F(1, 199) = 3.74, p = 0.055, see Figure 3. No
significant interaction effect was found between the presence of a positive screen for a
dissociative disorder according to the SDQ-20 and daily PCL-5 scores, F(4.42, 879.44) = 0.29,
p = 0.90.
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Figure 2. Mean CAPS-5 scores for those with and those without a positive screen on the SDQ-20, n = 219. CAPS-5,
Clinician-Administered PTSD Scale for DSM-5.
Figure 3. Mean PTSD Checklist for DSM-5 (PCL-5 scores) per treatment day for those with and without a positive screen on
the SDQ-20, n = 201.
3.3. Change in Somatoform Dissociative Symptoms Associated with Treatment
A significant main effect of time on the severity of somatoform dissociative symptoms
was found, F(1, 217) = 260.33, p < 0.001, Cohen’s d = 0.73. Additionally, a significant
interaction effect was found between a positive screen for a dissociative disorder according
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to the SDQ-20 and total SDQ-20 scores, F(1, 217) = 112.55, p < 0.001, partial η2 = 0.34,
suggesting that patients of the positive screen group showed a significantly greater decrease
in somatoform dissociative symptoms after treatment, as shown in Figure 4. Using the same
cut-off score as at intake, six patients (20.7%) still fulfilled the criteria of a positive screen
for a dissociative disorder based upon the SDQ-20 at post-treatment. A McNemar test
showed that this was a significantly smaller proportion of patients than before treatment,
χ2 = 17.93, p < 0.001. Furthermore, a significant positive correlation was found between
the decrease in PTSD symptoms and the decrease in somatoform dissociative symptoms,
r(212) = 0.19, p = 0.005. See also Table 2 for mean SDQ-20 scores.
Figure 4. Mean SDQ-20 scores for those with and without a positive screen on the SDQ-20, n = 219.
SDQ-5 scores decreased significantly over the treatment days, F(3.07, 603.82) = 53.97,
p < 0.001, partial η2 = 0.22. Additionally, a significant main effect of group was found,
F(1, 197) = 21.90, p <0.001, partial η2 = 0.10, indicating that those in the positive screen group
had higher SDQ-5 scores on all days than those in the negative screen group. Moreover, an
interaction effect was found, F(3.07, 603.82) = 7.45, p < 0.001, partial η2 = 0.04, indicating a
significantly larger decrease in somatoform dissociative symptoms for those with a positive
screen compared to those with a negative screen (see Figure 5).
3.4. Exploration of Follow-Up Data
To further investigate the potential influence of pre-treatment somatoform dissociative
symptoms on PTSD symptoms at 6 months’ follow-up, we conducted a simple regression
analysis with total pre-treatment SDQ-20 scores as the independent variable, and the
difference in total CAPS scores between pre-treatment and follow-up as the dependent
variable. No significant relationship was found, F(1, 117) = 3.69, p = 0.06, R2 = 0.03.
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Figure 5. Mean SDQ-5 scores per treatment day for those with and those without a positive screen on the SDQ-20, n = 199.
4. Discussion
The first aim of the present study was to determine the extent to which patients report-
ing a high level of somatoform dissociative symptoms, compared with those reporting a
low level, would benefit from an intensive trauma-focused treatment. The results showed
that PTSD symptom severity decreased significantly in both groups, with no differences in
PTSD symptom decrease between the groups. In addition to the pre- and post-treatment
results, during the treatment days the decrease in self-reported PTSD symptoms also did
not differ between the two groups. Furthermore, the severity of somatoform dissociation at
pre-treatment was not predictive of treatment outcome at post-treatment and six-months
follow-up in terms of PTSD symptom reduction.
These findings are in line with studies on psychological dissociative symptoms
(see [7]), in that dissociative symptoms do not seem to have a significant impact on the de-
crease in PTSD symptoms when trauma-focused therapy is administered without treating
dissociative symptoms first. To our knowledge, this is the first study that extends these
meta-analytic findings to somatoform dissociation. Both the lack of difference in PTSD
symptom reduction between the two groups and the fact that the low drop-out rate did not
differ between the two groups suggest that trauma-focused therapy is well-tolerated by
this subgroup of PTSD patients, and proved not, as some say, too overwhelming [21,40,41].
Emotional overmodulation, and the expected co-occurring difficulties with fear activa-
tion, might be less present among those with somatoform dissociative symptoms than
assumed [14,15]. This would imply that it is not imperative in treatment to first address
the somatoform dissociative symptoms before commencing with trauma-focused therapy,
because it does not notably impede trauma-focused therapy. Hence, when replicated, the re-
sults of our study indicate that trauma-focused therapy can also be applied as a first-choice
treatment for PTSD patients with additional somatoform dissociative symptoms.
The second aim of this study was to determine the extent to which somatoform disso-
ciative symptoms would decrease during treatment. The results showed that somatoform
dissociative symptoms decreased significantly, and that this decrease was larger for those
with high levels of somatoform dissociative symptoms. During the treatment program, the
decrease in somatoform dissociative symptoms was higher for those with high levels of
somatoform dissociation at pre-treatment. Interestingly, 23 (79.3%) of the 29 patients who
had high levels of somatoform dissociative symptoms at pre-treatment no longer scored
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above the cut-off score on the SDQ-20 at post-treatment, i.e., they lost their positive screen
for a dissociative disorder. These findings coincide with findings in other studies where
specific somatoform dissociative symptoms (i.e., seizure frequency) [22] or psychological
dissociative symptoms, e.g., [8,9], proved to decrease over the course of a trauma-focused
treatment. Lynch, Forman, Mendelsohn, and Herman [42] already noted that PTSD symp-
toms and dissociative symptoms tend to move together during treatment, confirmed by
the here observed significant correlation between the decrease in PTSD symptoms and
somatoform dissociative symptoms. As suggested before [9], this might indicate that
dissociative symptoms should be considered as being associated with PTSD, rather than a
distinct form of PTSD.
Furthermore, the results showed that the dissociative subtype of PTSD (i.e., psycho-
logical dissociative symptoms) was more often present among those with high levels of
somatoform dissociative symptoms than those with low levels of somatoform dissociative
symptoms. However, almost 25% of those with a high level of somatoform dissociative
symptoms did not meet the criteria of the dissociative subtype of PTSD. This is in line
with the notion by Holmes et al. [12] that both phenomena can occur together but also in
isolation of each other. Therefore, it is important that studies on dissociation and PTSD
also include measures of somatoform dissociation. Future research might shed light on the
dynamics between PTSD symptoms, psychological dissociative symptoms, and somato-
form dissociative symptoms through symptom-based analyses, for example, a network
model approach. Recent studies in this area showed, for instance, that psychological disso-
ciative symptoms cluster together with PTSD symptoms, especially re-experiencing [43,44].
However, these studies did not include somatoform dissociative symptoms, which would
be an interesting and important follow-up step.
This is the first study that examines somatoform dissociation in relation to PTSD
treatment outcome. Its relevance was shown by the direct clinical implications, namely
that, when replicated, PTSD patients with severe somatoform dissociative symptoms
do not have to be excluded from evidence-based, trauma-focused treatments. This is
important, given that somatoform dissociative symptoms are common among traumatized
individuals [45,46]. However, when interpreting the results of the current study, some
limitations need to be taken into account. The major limitation is the lack of sufficient
follow-up data. Yet, the purpose of the present study was to investigate the extent to
which PTSD patients with somatoform dissociative symptoms would respond to trauma-
focused treatment in comparison to patients without somatoform dissociative symptoms.
Studying only post-treatment outcomes enabled us to analyze moderating effects in a very
well controlled treatment period. It is nonetheless very important for future studies to
include non-selective follow-up data, in order to also examine the long-term course of
somatoform dissociative symptoms. Another limitation was the use of a self-report measure
for somatoform dissociation. Although the SDQ is a well-validated measure, and scores
above the cut-off score of the SDQ proved indicative of a dissociative disorder, the SDQ is a
screening measure and not an instrument for classifying dissociative disorders. Therefore,
our results cannot be generalized to patients with a dissociative disorder. A third limitation
was the lack of randomization in this study. Future research should compare treatment
programs such as the one used in this study with a phase-based approach in the form
of a randomized clinical trial, in order to be able to draw conclusions regarding possible
superiority in treatment approach. This was not the aim of this study, and our study design
was therefore different. Nonetheless, our results still contribute significantly, since we
found no difference in PTSD symptom decrease after an intensive trauma-focused treatment
between those with somatoform dissociative symptoms and those without. Another
limitation is that our findings were found in the context of an intensive treatment program,
so it is unclear whether our results can be generalized to trauma-focused treatments that are
delivered in a typical outpatient format with weekly sessions. One strength of the present
study is first and foremost that this is the first study to include somatoform dissociation in
the examination of predictors for PTSD treatment outcomes. Additional strengths include
J. Clin. Med. 2021, 10, 1553 10 of 12
the large sample size, the diversity of the sample regarding trauma history, and the use
of robust and valid measuring instruments. What is more, in addition to pre- and post-
treatment measures, changes in somatoform dissociation symptom severity were also
measured during the treatment program.
5. Conclusions
In conclusion, the present study showed no difference in PTSD symptom decrease
during and after an intensive trauma-focused therapy between those with a high level
versus a low level of somatoform dissociation, and the severity of somatoform dissociative
symptoms was not predictive of treatment outcome. Moreover, trauma-focused treatment
also led to a significant decrease in somatoform dissociative symptoms. These results
suggest that patients with PTSD and severe somatoform dissociative symptoms should not
be excluded from trauma-focused therapy.
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